Uncategorized

US ‘eroding’ lead in rare diseases a matter of national security: Report

Published

on

A Congressional advisory panel recommends the U.S. government put supportive policies in place for rare disease drug development, such as a finalized platform designation from the FDA and the allowance of novel trial designs for small patient populations.

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version